NDA 020164 · Sanofi Aventis US
Lovenox (Preservative Free)
Enoxaparin Sodium · Subcutaneous, Intravenous, Subcutaneous
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Jul 28, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1993
Mar 29, 1993
Approved uses
9
Original approval plus efficacy supplements
Registered trials
421
139 Phase 3, 34 recruiting
FAERS reports
58,051
50,417 serious, 8,973 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: Use of indwelling epidural catheters Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, and other anticoagulants A history of traumatic or repeated epidural or spinal punctures A history of spinal deformity or spinal surgery Optimal timing between the administration of enoxaparin sodium and neuraxial procedures is not known Monitor patients...
What it is approved for
From the label in effect Sep 17, 2026.
Enoxaparin sodium is a low molecular weight heparin (LMWH) indicated for: Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness ( 1.1 ) Inpatient treatment of acute DVT with or without pulmonary embolism ( 1.2 ) Outpatient treatment of acute DVT without pulmonary embolism ( 1.2 ) Prophylaxis of ischemic complications of unstable angina and non–Q-wave myocardial infarction (MI) ( 1.3 ) Treatment of acute ST-segment elevation myocardial infarction (STEMI) managed medically or with subsequent percutaneous coronary intervention (PCI) ( 1.4 ) 1.1 Prophylaxis of Deep Vein Thrombosis Enoxaparin sodium is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE): in patients undergoing abdominal surgery who are at risk for thromboembolic complications [see Clinical Studies (14.1) ] in patients undergoing hip replacement surgery, during and following hospitalization in patients undergoing knee replacement surgery in medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness 1.2 Treatment of Acute Deep Vein Thrombosis Enoxaparin sodium is indicated for: the inpatient treatment of acute deep vein thrombosis with or without pulmonary embolism , when administered in conjunction with warfarin sodium the outpatient treatment of acute deep vein thrombosis without pulmonary embolism, when administered in conjunction with warfarin sodium 1.3 Prophylaxis of Ischemic Complications of Unstable Angina and Non–Q-Wave Myocardial Infarction Enoxaparin sodium is indicated for the prophylaxis of ischemic complications of unstable angina and non–Q-wave...
Mechanism: Enoxaparin is a low molecular weight heparin which has antithrombotic properties.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 17, 2000 Supplement 36 · Efficacy · priority review LetterLabel
- Aug 3, 2000 Supplement 20 · Efficacy Letter
- May 30, 2000 Supplement 34 · Efficacy Letter
- Dec 31, 1998 Supplement 15 · Efficacy ReviewLetterLabel
- Mar 27, 1998 Supplement 16 · Efficacy · priority review
- Jan 30, 1998 Supplement 10 · Efficacy ReviewLetter
- May 6, 1997 Supplement 8 · Efficacy
- Mar 9, 1995 Supplement 2 · Efficacy
- Mar 29, 1993 Original approval · Type 1 - New Molecular Entity · priority review Other Important Information from FDAReviewLetter
9 products under this application
- LOVENOX (PRESERVATIVE FREE) · ENOXAPARIN SODIUM 40MG/0.4ML (100MG/ML) · INJECTABLE, SUBCUTANEOUS · Prescription · TE AP
- LOVENOX · ENOXAPARIN SODIUM 300MG/3ML (100MG/ML) · INJECTABLE, INTRAVENOUS, SUBCUTANEOUS · Prescription · TE AB
- LOVENOX (PRESERVATIVE FREE) · ENOXAPARIN SODIUM 120MG/0.8ML (150MG/ML) · INJECTABLE, SUBCUTANEOUS · Prescription · TE AP
- LOVENOX (PRESERVATIVE FREE) · ENOXAPARIN SODIUM 100MG/ML (100MG/ML) · INJECTABLE, SUBCUTANEOUS · Prescription · TE AP
- LOVENOX (PRESERVATIVE FREE) · ENOXAPARIN SODIUM 60MG/0.6ML (100MG/ML) · INJECTABLE, SUBCUTANEOUS · Prescription · TE AP
- LOVENOX (PRESERVATIVE FREE) · ENOXAPARIN SODIUM 30MG/0.3ML (100MG/ML) · INJECTABLE, SUBCUTANEOUS · Prescription · TE AP
- LOVENOX (PRESERVATIVE FREE) · ENOXAPARIN SODIUM 150MG/ML (150MG/ML) · INJECTABLE, SUBCUTANEOUS · Prescription · TE AP
- LOVENOX (PRESERVATIVE FREE) · ENOXAPARIN SODIUM 90MG/0.6ML (150MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, SUBCUTANEOUS · Discontinued
- LOVENOX (PRESERVATIVE FREE) · ENOXAPARIN SODIUM 80MG/0.8ML (100MG/ML) · INJECTABLE, SUBCUTANEOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Enoxaparin" as an intervention, any sponsor and status, largest first.
- Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00077792 · 20,506 participants · Start Oct 2002 · Primary completion Dec 2006
Drug: Enoxaparin sodium (XRP4563) · For: Myocardial Infarction; Acute ST-Segment Elevation
Sites: Bridgewater, New Jersey; Buenos Aires, Argentina; Macquarie Park, Australia · 48 sites in all
- Michelangelo - Oasis 5Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00139815 · 20,078 participants · Start Apr 2003 · Primary completion Dec 2005
Drug: Fondaparinux; enoxaparin · For: Thromboembolism
- Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)Pivotal-lookingCompleted
The Medicines CompanyIndustry
NCT00093158 · 13,800 participants · Start Aug 2003
Drug: Angiomax (bivalirudin) anticoagulant · For: Unstable Angina; Myocardial Infarction; Acute Disease
Sites: New York, New York
- PREVENTion of Clot in Orthopaedic TraumaPivotal-lookingCompleted
Major Extremity Trauma Research ConsortiumAcademic, hospital or other
NCT02984384 · 12,424 participants · Start Apr 24, 2017 · Primary completion Feb 18, 2022
Drug: Acetylsalicylic acid; Low Molecular Weight Heparin (LMWH) · For: Blood Clot; Trauma
Sites: Tucson, Arizona; Miami, Florida; Indianapolis, Indiana · 21 sites in all
- Thromboprophylaxis in Lower Limb ImmobilisationPivotal-lookingRecruiting
Queen Mary University of LondonAcademic, hospital or other
NCT06370273 · 10,044 participants (planned) · Start Nov 12, 2024 · Primary completion Aug 31, 2028
Drug: Rivaroxaban; Apixaban and 4 more · For: Thrombosis; Injury Leg
Sites: Carshalton, United Kingdom; Hull, United Kingdom; London, United Kingdom · 5 sites in all
- Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum ThrombosisPivotal-lookingRecruiting
Marc BlondonAcademic, hospital or other
NCT07140211 · 9,200 participants (planned) · Start Oct 15, 2025 · Primary completion Aug 2030
Drug: Low-dose low-molecular-weight heparin · For: Venous Thromboembolism (VTE); Postpartum
Sites: Baden, Switzerland; Basel, Switzerland; Bern, Switzerland · 9 sites in all
- The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue MorbidityPivotal-lookingRecruiting
University of CalgaryAcademic, hospital or other
NCT06494878 · 8,805 participants (planned) · Start Jun 4, 2026 · Primary completion Sep 2030
Drug: Aspirin; Low-molecular-weight heparin · For: Venous Thromboembolism; Postpartum Period; Aspirin and 1 more
Sites: Brussels, Belgium; Calgary, Canada; Ottawa, Canada · 12 sites in all
- Study to Evaluate the Mortality Reduction of Enoxaparin in Hospitalized Acutely Ill Medical Receiving EnoxaparinPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00622648 · 8,329 participants · Start Jan 2008 · Primary completion Dec 2010
Drug: Enoxaparin; Placebo · For: Acute Illness
Sites: São Paulo, Brazil; Shanghai, China; Hong Kong, Hong Kong · 9 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use2,665
- dyspnoea2,456
- nausea2,434
- diarrhoea2,330
- anaemia2,259
- thrombocytopenia2,131
- pyrexia2,098
- fatigue2,034
- vomiting1,905
- pulmonary embolism1,831
- death1,772
- pneumonia1,716
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,257 |
| 2005 | 1,329 |
| 2006 | 1,244 |
| 2007 | 1,240 |
| 2008 | 1,501 |
| 2009 | 1,763 |
| 2010 | 1,941 |
| 2011 | 2,327 |
| 2012 | 2,297 |
| 2013 | 1,935 |
| 2014 | 2,315 |
| 2015 | 2,754 |
| 2016 | 2,904 |
| 2017 | 2,745 |
| 2018 | 3,649 |
| 2019 | 3,436 |
| 2020 | 3,596 |
| 2021 | 3,368 |
| 2022 | 3,956 |
| 2023 | 3,666 |
| 2024 | 3,309 |
| 2025 | 3,268 |
| 2026 | 2,249 |
Recalls
1 FDA enforcement reports for this application.
Dec 5, 2017 · Class III · Terminated
Labeling: Label Error on Declared Strength. A single syringe labeled as 150 mg/1.0 mL was found packaged in a blister labeled as 120 mg/mL
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Oct 20, 2026
Lovenox, Injection, 100 mg/1 mL (NDC 0075-0623-00). Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin...
To Be Discontinued · updated Oct 20, 2026
Enoxaparin Sodium, Injection, 100 mg/1 mL (NDC 0955-1010-10). Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic...
To Be Discontinued · updated Oct 20, 2026
Lovenox, Injection, 300 mg/3 mL (NDC 0075-0626-03). Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin...
To Be Discontinued · updated Oct 20, 2026
Enoxaparin Sodium, Injection, 300 mg/3 mL (NDC 0955-1016-01). Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic...
To Be Discontinued · updated Oct 20, 2026
Lovenox, Injection, 40 mg/.4 mL (NDC 0075-8014-10). Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin...
To Be Discontinued · updated Oct 20, 2026
Lovenox, Injection, 30 mg/.3 mL (NDC 0075-0624-30). Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin...
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lovenox (Enoxaparin Sodium)
2024 spending
$577K
Beneficiaries
392
950 claims
Per beneficiary
$1,471
$24.80 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,499,490 |
| 2021 | $2,848,286 |
| 2022 | $1,795,726 |
| 2023 | $675,990 |
| 2024 | $576,582 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial.
Sidhu VS, Kelly TL, Pratt N, et al. · JAMA 2022 · Comparative Study, Multicenter Study
- Enoxaparin for COVID-19: a systematic review and meta-analysis of randomized controlled trials.
Ehsan M, Jafar U, Butt M, et al. · J Thromb Thrombolysis 2023 · Meta-Analysis, Systematic Review
- Abelacimab for Prevention of Venous Thromboembolism.
Verhamme P, Yi BA, Segers A, et al. · N Engl J Med 2021 · Comparative Study, Randomized Controlled Trial
- Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial.
Zhou S, Xiao Y, Zhou C, et al. · JAMA Netw Open 2023 · Randomized Controlled Trial, Multicenter Study
- Factor XI Inhibitors in Early Clinical Trials: A Meta-analysis.
Galli M, Laborante R, Ortega-Paz L, et al. · Thromb Haemost 2023 · Systematic Review, Meta-Analysis
- Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-Analysis.
Jacobson B, Rambiritch V, Paek D, et al. · Adv Ther 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Sanofi · Also marketed as Lovenox
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.